Selected recent trials evaluating second cancers in patients treated for Hodgkin’s lymphoma.
| . | . | . | . | No. of Pts. with Second Cancers . | Relative Risk# . | Absolute Excess Risk‡ . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author . | Years of Accrual . | No. of Treated Patients . | Range of Follow-up . | All Cancers . | Solid Tumors (% of second cancers) . | Leukemia . | All Cancers . | Solid Tumors . | Leukemia . | All Cancers . | Solid Tumors (% of second cancers) . | Leukemia . |
| # Relative risk refers to the ratio of observed vs. expected events | ||||||||||||
| ‡ Absolute excess risk refers to the number of observed events minus expected events per 10,000 patient–years of follow-up | ||||||||||||
| * eligibility restricted to patients less than 40 years of age when treated for Hodgkin’s lymphoma | ||||||||||||
| ** eligibility restricted to patients less than 21 years of age when treated for Hodgkin’s lymphoma | ||||||||||||
| *** eligibility restricted to patients less than 16 years of age when treated for Hodgkin’s lymphoma | ||||||||||||
| Abbreviations: ns, not stated; nd, not determined | ||||||||||||
| Dores16 | 1935–1994 | 32,591 | 1 – > 30 yrs (mean = 7.8 yrs; > 15 yrs = 19%) | 2,153 | 1,726 (80) | 249 (12) | 2.3 | 2.0 | 9.9 | 47.2 | 33.1 (68) | 8.8 (19) |
| Swerdlow17 | 1963–1993 | 5,519 | 1 – > 25 yrs (mean 8.5 yrs) | 322 | 227 (70) | 45 (14) | 2.9 | ns | 14.6 | 44.5 | 25.9 (58) | 8.9 (20) |
| Ng18 | 1969–1997 | 1,319 | < 1 – > 20 yrs (median 12 yrs) | 181 | 131 (72) | 23 (13) | 4.6 | 3.5 | 82.5 | 89.3 | 59.1 (66) | 14.3 (16) |
| Van Leeuwen19* | 1966–1986 | 1,253 | 1 – > 20 yrs (median 14.1 yrs) | 137 | 106 (77) | 18 (13) | 7.0 | 6.1 | 37.5 | 2.3 | 54.5 (75) | 10.8 (15) |
| Metayer20** | 1935–1994 | 5,925 | 1 – > 20 yrs (mean = 10.5 yrs; > 15 yrs = 27%) | 195 | 157 (81) | 28 (14) | 7.7 | 7.0 | 20.9 | ns | 24.0 nd | ns nd |
| Bhatia21*** | 1955–1986 | 1,380 | 0.1 – 37 yrs (median 11.4 yrs) | 79 | 47 (59) | 26 (33) | 18.8 | 11.8 | 78.8 | ns | ns nd | ns nd |
| . | . | . | . | No. of Pts. with Second Cancers . | Relative Risk# . | Absolute Excess Risk‡ . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author . | Years of Accrual . | No. of Treated Patients . | Range of Follow-up . | All Cancers . | Solid Tumors (% of second cancers) . | Leukemia . | All Cancers . | Solid Tumors . | Leukemia . | All Cancers . | Solid Tumors (% of second cancers) . | Leukemia . |
| # Relative risk refers to the ratio of observed vs. expected events | ||||||||||||
| ‡ Absolute excess risk refers to the number of observed events minus expected events per 10,000 patient–years of follow-up | ||||||||||||
| * eligibility restricted to patients less than 40 years of age when treated for Hodgkin’s lymphoma | ||||||||||||
| ** eligibility restricted to patients less than 21 years of age when treated for Hodgkin’s lymphoma | ||||||||||||
| *** eligibility restricted to patients less than 16 years of age when treated for Hodgkin’s lymphoma | ||||||||||||
| Abbreviations: ns, not stated; nd, not determined | ||||||||||||
| Dores16 | 1935–1994 | 32,591 | 1 – > 30 yrs (mean = 7.8 yrs; > 15 yrs = 19%) | 2,153 | 1,726 (80) | 249 (12) | 2.3 | 2.0 | 9.9 | 47.2 | 33.1 (68) | 8.8 (19) |
| Swerdlow17 | 1963–1993 | 5,519 | 1 – > 25 yrs (mean 8.5 yrs) | 322 | 227 (70) | 45 (14) | 2.9 | ns | 14.6 | 44.5 | 25.9 (58) | 8.9 (20) |
| Ng18 | 1969–1997 | 1,319 | < 1 – > 20 yrs (median 12 yrs) | 181 | 131 (72) | 23 (13) | 4.6 | 3.5 | 82.5 | 89.3 | 59.1 (66) | 14.3 (16) |
| Van Leeuwen19* | 1966–1986 | 1,253 | 1 – > 20 yrs (median 14.1 yrs) | 137 | 106 (77) | 18 (13) | 7.0 | 6.1 | 37.5 | 2.3 | 54.5 (75) | 10.8 (15) |
| Metayer20** | 1935–1994 | 5,925 | 1 – > 20 yrs (mean = 10.5 yrs; > 15 yrs = 27%) | 195 | 157 (81) | 28 (14) | 7.7 | 7.0 | 20.9 | ns | 24.0 nd | ns nd |
| Bhatia21*** | 1955–1986 | 1,380 | 0.1 – 37 yrs (median 11.4 yrs) | 79 | 47 (59) | 26 (33) | 18.8 | 11.8 | 78.8 | ns | ns nd | ns nd |